In brief: Acrux, Proteome Systems, Panbio, Virax
Tuesday, 31 January, 2006
Ross Dobinson has been appointed as Acrux's (ASX:ACR) non-executive chairman, replacing Nuno D'Aquino who is stepping down due to private commitments. D'Aquino will continue as a non-executive director and will chair the board's Human Capital Committee.
Dobinson is a founder and former CEO of Acrux and has an 8 per cent interest in the company's shares. Ken Windle, an Acrux director since 2001, has been appointed non-executive deputy chairman.
Following a letter of intent announced at BIO 2005, Proteome Systems (ASX:PXL) has signed a formal agreement with the Bill Gates-funded Foundation for Innovative New Diagnostics (FIND) to develop Proteome's tuberculosis biomarkers for incorporation into a point-of-care test. The agreement details development milestones and financial and non-financial commitments.
Panbio (ASX:PBO) has appointed Peter Burrows as CFO and company secretary permanently. He was originally appointed on an interim basis on August 27.
Virax Holdings (ASX:VHL) has raised a further $600,000 under its rights issue, bringing the total raised to $3.7 million out of $3.8 million. The issue will close on February 15.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
